Journal of Clinical Pharmacology

Article	Citations
Severe Acute Lung Injury Related to COVID‐19 Infection: A Review and the Possible Role for Escin	79
Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018‐2019 Submissions to the US FDA's Office of Clinical Pharm	70
TMPRSS2: Potential Biomarker for COVID‐19 Outcomes	61
A Comprehensive Review of Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome	54
PEG That Reaction: A Case Series of Allergy to Polyethylene Glycol	53
MDMA‐Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta‐Analysis	40
Baricitinib: From Rheumatoid Arthritis to COVID‐19	37
Differential Binding of Sarilumab and Tocilizumab to IL‐6Rα and Effects of Receptor Occupancy on Clinical Parameters	29
Nonparametric Methods in Population Pharmacokinetics	28
Pharmacology of Drugs Used as Stimulants	27
Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti‐Activin A): Results From a First‐in‐Human Phase 1 Study	27
Empiric Therapeutic Anticoagulation and Mortality in Critically Ill Patients With Respiratory Failure From SARS‐CoV‐2: A Retrospective Cohort Study	26
Does “Birth” as an Event Impact Maturation Trajectory of Renal Clearance via Glomerular Filtration? Reexamining Data in Preterm and Full‐Term Neonates by Avoiding the Creatinine Bias	25
A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam	25
Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic‐Pharmacodynamic Modeling Approaches	23
SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database	23
Discordance Between Child‐Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds	23
Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential	22
Neurological Immune‐Related Adverse Events After COVID‐19 Vaccination: A Systematic Review	22
Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites	22
Continued Risk of Dietary Supplements Adulterated With Approved and Unapproved Drugs: Assessment of the US Food and Drug Administration's Tainted Supplements Database 2007 Through 2021	22
Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation	22
The Epidemiology of Drug Abuse	21
Demonstrating Feasibility of an Opportunistic Sampling Approach for Pharmacokinetic Studies of β‐Lactam Antibiotics in Critically Ill Children	21
Can Colchicine as an Old Anti‐Inflammatory Agent Be Effective in COVID‐19?	20

Clinical Outcome Data of First Cohort of Chronic Pain Patients Treated With Cannabis‐Based Sublingual Oils in the United Kingdom: Analysis From the UK Medical Cannabis Registry	19
Potential COVID‐19 Therapeutic Agents and Vaccines: An Evidence‐Based Review	19
CD33‐Targeted Therapies: Beating the Disease or Beaten to Death?	18
Antiretrovirals for Prophylaxis Against COVID‐19: A Comprehensive Literature Review	18
Natural History and Real‐World Data in Rare Diseases: Applications, Limitations, and Future Perspectives	18
A Physiological Approach to Pharmacokinetics in Chronic Kidney Disease	18
Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Pro	17
Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects	17
Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions	17
Pharmacogenomics and Morphine	16
Clinical Pharmacology of Electronic Nicotine Delivery Systems (ENDS): Implications for Benefits and Risks in the Promotion of the Combusted Tobacco Endgame	16
Clinical Pharmacology, Toxicity, and Abuse Potential of Opioids	16
Parametric Approaches in Population Pharmacokinetics	16
Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation	15
Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder	15
Hydroxychloroquine and Azithromycin to Treat Patients With COVID‐19: Both Friends and Foes?	15
Metabolism, Excretion, and Pharmacokinetics of Lorlatinib (PF‐06463922) and Evaluation of the Impact of Radiolabel Position and Other Factors on Comparability of Data Across 2 ADME Studies	15
Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis	15
Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability	15
Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches	14
Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients	14
Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia	14
Fetal Arrhythmia Diagnosis and Pharmacologic Management	13
Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate	13
Randomized Crossover Trial to Compare Abuse Liability of Intravenous Remimazolam Versus Intravenous Midazolam and Placebo in Recreational Central Nervous System Depressant Users	13
Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites	13
Pharmacological Predictors of Morbidity and Mortality in COVID‐19	13
Model‐Aided Adults‐to‐Children Pharmacokinetic Extrapolation and Empirical Body Size‐Based Dosing Exploration for Therapeutic Monoclonal Antibodies—Is Allometry a Reasonable Choice?	13
Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing	12
Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients	12
Drug Combination Modeling: Methods and Applications in Drug Development	12
A Comprehensive Updated Review on SARS‐CoV‐2 and COVID‐19	12
Drug Disposition in Subjects With Obesity: The Research Work of Darrell R. Abernethy	12
Amantadine for COVID‐19	12
Factors Influencing Change in Serum Uric Acid After Administration of the Sodium‐Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus	12
Racial and Ethnic Differences in Drug Disposition and Response: Review of New Molecular Entities Approved Between 2014 and 2019	12
Sedative‐Hypnotic Agents That Impact Gamma‐Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma‐Hydroxybutyric Acid, Phenibut, and Selank	12
Therapeutic Application of Corticosteroids in COVID‐19: A Focus on Optimum Dose and Duration of Therapy	11
Further Evaluation of Coproporphyrins as Clinical Endogenous Markers for OATP1B	11
Assessment of Clinical Drug‐Drug Interactions of Elagolix, a Gonadotropin‐Releasing Hormone Receptor Antagonist	11
Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder	11
Rivaroxaban as an Alternative Agent for Heparin‐Induced Thrombocytopenia	11
Utility of Quantitative Proteomics for Enhancing the Predictive Ability of Physiologically Based Pharmacokinetic Models Across Disease States	11
Exposure‐Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials	11
Optimal Dosing of Meropenem in a Small Cohort of Critically Ill Children Receiving Continuous Renal Replacement Therapy	10
Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation	10
Pharmacokinetics and Pharmacodynamics of Tegoprazan Coadministered With Amoxicillin and Clarithromycin in Healthy Subjects	10
Neonatal and Childhood Outcomes in Offspring of Pregnant Women Using Antidepressant Medications: A Critical Review of Current Meta‐Analyses	10
A Retrospective Analysis of Intravenous vs Oral Antibiotic Step‐Down Therapy for the Treatment of Uncomplicated Streptococcal Bloodstream Infections	10
Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials	10

Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma	10
Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts’ Discussion on Use, Strengths, and Limitations	10
Drug‐Drug Interaction Studies With Oral Contraceptives: Pharmacokinetic/Pharmacodynamic and Study Design Considerations	10
Usage of In Vitro Metabolism Data for Drug‐Drug Interaction in Physiologically Based Pharmacokinetic Analysis Submissions to the US Food and Drug Administration	10
Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects	10
Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects	10
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment	10
Predictive Performance of Physiology‐Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small‐Molecule Compounds in Children	10
The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations	10
Postmenopausal Hormone Therapy—Local and Systemic: A Pharmacologic Perspective	10
Can PBPK Modeling Streamline Food Effect Assessments?	10
Proposal of a Safe and Effective Study Design for CYP3A‐Mediated Drug‐Drug Interactions	10
Ketamine for Refractory Chronic Migraine: An Observational Pilot Study and Metabolite Analysis	9
Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients	9
Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model‐Informed Dose Selection for Pediatric Development	9
Application of Physiologically Based Pharmacokinetic‐Pharmacodynamic Modeling in Preterm Neonates to Guide Gentamicin Dosing Decisions and Predict Antibacterial Effect	9
Caplacizumab Model‐Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura	9
A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure	9
Factors Affecting Contraception Access and Use in Patients With Opioid Use Disorder	9
Use of Real‐World Data and Pharmacometric Modeling in Support of Lacosamide Dosing in Pediatric Patients Under 4 Years of Age	9
Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy	9
Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA‐HF Study Population: A Mathematical Modeling Analysis	9
Physiologically Based Pharmacokinetic Modeling of Metformin in Children and Adolescents With Obesity	9
The Interplay Between the Immune System, the Renin‐Angiotensin‐Aldosterone System (RAAS), and RAAS Inhibitors May Modulate the Outcome of COVID‐19: A Systematic Review	9
Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection	9
Influence of Prednisone on Inflammatory Biomarkers in Community‐Acquired Pneumonia: Secondary Analysis of a Randomized Trial	9
Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa)	9
Pediatric Dose Selection for Therapeutic Proteins	9
Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens	9
Considerations for Drug Dosing in Premature Infants	9
Evaluation and Development of Vancomycin Dosing Schemes to Meet New AUC/MIC Targets in Intermittent Hemodialysis Using Monte Carlo Simulation Techniques	9
QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small‐Molecule New Drug Applications Approved During 2011‐2019	9
Off‐Label Use of Hydroxychloroquine in COVID‐19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance	9
Population Pharmacokinetic Modeling and Simulations of Imipenem in Burn Patients With and Without Continuous Venovenous Hemofiltration in the Military Health System	8
A Population Pharmacokinetic Meta‐Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients	8
Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein	8
Population Pharmacokinetics and Exposure‐Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β‐Thalassemia	8
Huntington's Disease Progression: A Population Modeling Approach to Characterization Using Clinical Rating Scales	8
Pediatric Drug‐Drug Interaction Evaluation: Drug, Patient Population, and Methodological Considerations	8
Exposure‐Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy	8
An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants	8
Physiologically Based Pharmacokinetic Model‐Informed Drug Development for Polatuzumab Vedotin: Label for Drug‐Drug Interactions Without Dedicated Clinical Trials	8
Enhancing Pediatric Adverse Drug Reaction Documentation in the Electronic Medical Record	8
Vedolizumab Immunogenicity With Long‐Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease	8
Talazoparib Exposure‐Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial	8
Using Endogenous Biomarkers to Derisk Assessment of Transporter‐Mediated Drug‐Drug Interactions: A Scientific Perspective	8
Fever Associated With Dexmedetomidine in Adult Acute Care Patients: A Systematic Review of the Literature	8
Clinical Pharmacology Considerations on Recombinant Adeno‐Associated Virus–Based Gene Therapy	8
Model‐Informed Drug Development in Pediatric Dose Selection	8
Inclisiran: A Novel Small Interfering RNA Drug for Low‐Density Lipoprotein Reduction	8
Effect of Body Fat on Population Pharmacokinetics of High‐Dose Methotrexate in Pediatric Patients With Acute Lymphoblastic Leukemia	8
Model‐Informed Dose Optimization in Pregnancy	8
Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors	8
Slow Accumulation and Elimination of Diazepam and Its Active Metabolite With Extended Treatment in the Elderly	8
A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A	7
Treatment With Tocilizumab for Patients With COVID‐19 Infections: A Case‐Series Study	7
Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates	7
Target‐Mediated Drug Disposition—A Class Effect of Soluble Epoxide Hydrolase Inhibitors	7
Heterogeneity in the Identification of Potential Drug‐Drug Interactions in the Intensive Care Unit: A Systematic Review, Critical Appraisal, and Reporting Recommendations	7
Population Pharmacokinetics and Bayesian Estimation of the Area Under the Concentration‐Time Curve for Ganciclovir in Adult Chinese Renal Allograft Recipients After Valganciclovir Administration	7
Corticosteroids in COVID‐19: We Should Be Mindful of Their Acute Toxicities	7
Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications	7
Assessment of Transporter‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	7
Predicting Human Fetal Drug Exposure Through Maternal‐Fetal PBPK Modeling and In Vitro or Ex Vivo Studies	7
Biperiden Challenge Model in Healthy Elderly as Proof‐of‐Pharmacology Tool: A Randomized, Placebo‐Controlled Trial	7
Model‐Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases	7
Estimation of Attainment of Steady‐State Conditions for Compounds With a Long Half‐Life	7
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition	7
Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses	7
Use of Propensity Scoring and Its Application to Real‐World Data: Advantages, Disadvantages, and Methodological Objectives Explained to Researchers Without Using Mathematical Equations	7
Immunomodulatory Therapeutic Proteins in COVID‐19: Current Clinical Development and Clinical Pharmacology Considerations	7
Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir	6
Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware	6
Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6‐Mediated Drug‐Drug Interactions on Tramadol and O‐Desmethyltramadol Exposures via Allosteric and Competitive Inhibition	6
Pharmacokinetics and Concentration‐Response of Dupilumab in Patients With Seasonal Allergic Rhinitis	6
Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis	6
Antibody‐Mediated Rejection in Adult Liver Transplant Recipients: A Case Series and Literature Review	6
Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment	6
Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment	6
Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Usi	6

Impact of Anxiety or Depression Symptoms on Propofol Requirements for Sedation in Females: A Prospective Cohort Study	6
Overmedication in COVID‐19 Context: A Report From Peru	6
Dose‐Related Adverse Drug Events in Neonates: Recognition and Assessment	6
Prostatic Pharmacokinetic/Pharmacodynamic Evaluation of Ampicillin‐Sulbactam for Bacterial Prostatitis and Preoperative Prophylaxis	6
Days Needed for the Disappearance of a Cough Due to the Use of an Angiotensin‐Converting Enzyme Inhibitor and Identification of Predisposing Factors Associated With Its Appearance in a Clinical Cohort	6
Informing Development of Bispecific Antibodies Using Physiologically Based Pharmacokinetic‐Pharmacodynamic Models: Current Capabilities and Future Opportunities	6
Application of Microdosed Intravenous Omeprazole to Determine Hepatic CYP2C19 Activity	6
The European Medicines Agency Experience With Pediatric Dose Selection	6
Pharmacokinetic/Pharmacodynamic Parameters of Linezolid in the Epithelial Lining Fluid of Patients With Sepsis	6
An Adaptive Physiologically Based Pharmacokinetic–Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers	6
Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus	6
Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia	6
Risk of SARS‐CoV‐2 Infection and COVID‐19 Severity Associated With Exposure to Nonsteroidal Anti‐Inflammatory Drugs: Systematic Review and Meta‐Analysis	6
Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta‐Analysis and Systematic Review	6
Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4‐Mediated Metabolism of Saxagliptin	6
Maternal Exposure and Neonatal Effects of Drugs of Abuse	6
Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment	6
Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?	6
Efficacy and Safety of Adjunctive Serotonin‐Dopamine Activity Modulators in Major Depression: A Meta‐Analysis of Randomized Controlled Trials	6
Evaluation of Drug‐Drug Interactions of Ensitrelvir, a SARS‐CoV‐2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies	6
Status Toward the Implementation of Precision Dosing in Children	6
The Current Landscape of Novel Formulations and the Role of Mathematical Modeling in Their Development	6
Clinical Pharmacology Considerations for Developing Small‐Molecule Treatments for COVID‐19	6
Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure Time	6
Dosing Recommendations for Pediatric Patients With Renal Impairment	6
Considerations and Challenges in the Remdesivir COVID‐19 Pediatric Development Program	6
Personalized Dosing of Infliximab in Patients With Inflammatory Bowel Disease Using a Bayesian Approach: A Next Step in Therapeutic Drug Monitoring	6
Pharmacokinetics of Hydrochlorothiazide in Children: A Potential Surrogate for Renal Secretion Maturation	6
Comparison of the Effects of Low‐Molecular‐Weight Heparin and Fondaparinux on Liver Function in Patients With Pulmonary Embolism	6
The New S7B/E14 Question and Answer Draft Guidance for Industry: Contents and Commentary	6
Prediction of Fracture Risk From Early‐Stage Bone Markers in Patients With Osteoporosis Treated With Once‐Yearly Administered Zoledronic Acid	6
Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Chinese Infants	5
The Importance of Clinical Research in Pregnant Women to Inform Prescription Drug Labeling	5
Direct Oral Anticoagulants: An Updated Systematic Review of Their Clinical Pharmacology and Clinical Effectiveness and Safety in Patients With Nonvalvular Atrial Fibrillation	5
Extrapolation of Efficacy and Dose Selection in Pediatrics: A Case Example of Atypical Antipsychotics in Adolescents With Schizophrenia and Bipolar I Disorder	5
Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P‐Glycoprotein Inhibitor (Itraconazole)	5
Association Between Baclofen and Respiratory Depression in Patients With Chronic Kidney Disease	5
Population Pharmacokinetics and Pharmacodynamics of Norvancomycin in Children With Malignant Hematological Disease	5
Buprenorphine Continuation During Critical Illness Associated With Decreased Inpatient Opioid Use in Individuals Maintained on Buprenorphine for Opioid Use Disorder in a Retrospective Study	5
Science and Evidence‐Based Review and Approval of COVID‐19 Vaccines: A Statement of Support for the US FDA	5
Colchicine and COVID‐19	5
Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis	5
Physiologically Based Pharmacokinetics as a Component of Model‐Informed Drug Development: Where We Were, Where We Are, and Where We Are Heading	5
A Target‐Mediated Drug Disposition Model to Explain Nonlinear Pharmacokinetics of the 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor SPI‐62 in Healthy Adults	5
Pain Management Considerations in Patients With Opioid Use Disorder Requiring Critical Care	5
A Clinical Decision Support Tool to Find the Best Initial Intravenous Cyclosporine Regimen in Pediatric Hematopoietic Stem Cell Transplantation	5
Outcomes Associated With 4‐Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients	5
Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study	5
Direct Oral to Parenteral Anticoagulants: Strategies for Inpatient Transition	5
The Nocebo Response in Pharmacologic Treatments of Primary Headache: A Systematic Review and Meta‐Analysis	5
Hypophosphatemia Is Common After Intravenous Ferric Carboxymaltose Infusion Among Patients With Symptomatic Heart Failure With Reduced Ejection Fraction	5
Lithium Pharmacokinetics in the Perinatal Patient With Bipolar Disorder	5
Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin	5
A Systematic Review of Intravaginal Diazepam for the Treatment of Pelvic Floor Hypertonic Disorder	5
Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations	5
Pharmacogenomics for Drug Dosing in Children: Current Use, Knowledge, and Gaps	5
Population Pharmacokinetics of Phenobarbital in Neonates and Infants on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy	5
Minors and a Dawning Paradigm Shift in “Pediatric” Drug Development	5
A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition	5
Methods Used for Pediatric Dose Selection in Drug Development Programs Submitted to the US FDA 2012‐2020	5
Drug–Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives	5
Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab	5
Population Pharmacokinetic Modeling of Cyclosporine Among Malaysian Renal Transplant Patients: An Evaluation of Methods to Handle Missing Doses in Conventional Drug‐Monitoring Data	5
A Population Pharmacokinetic Model of (R)‐ and (S‐) Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers	5